在慢性淋巴细胞白血病的异基因干细胞移植后，额外使用阿仑单抗是否会消除移植物抗白血病效应？ - Suppr | 超能文献

Does extra alemtuzumab remove the graft-versus-leukemia effect after allogeneic stem cell transplantation in chronic lymphocytic leukemia?

作者信息

Savani Bipin N, Goodman Stacey, Reddy Nishitha

出版信息

Biol Blood Marrow Transplant. 2009 Apr;15(4):517-8. doi: 10.1016/j.bbmt.2008.12.511.

DOI:10.1016/j.bbmt.2008.12.511

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Does extra alemtuzumab remove the graft-versus-leukemia effect after allogeneic stem cell transplantation in chronic lymphocytic leukemia?在慢性淋巴细胞白血病的异基因干细胞移植后，额外使用阿仑单抗是否会消除移植物抗白血病效应？

Biol Blood Marrow Transplant. 2009 Apr;15(4):517-8. doi: 10.1016/j.bbmt.2008.12.511.

2

The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.使用阿仑单抗进行体内T细胞清除对慢性淋巴细胞白血病减低强度异基因造血细胞移植的影响。

Biol Blood Marrow Transplant. 2008 Nov;14(11):1288-97. doi: 10.1016/j.bbmt.2008.09.001.

3

Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen.在清髓性预处理方案中使用阿仑单抗，对首次或第二次缓解期的急性淋巴细胞白血病儿童进行替代供体和匹配同胞供体造血干细胞移植的可比结果。

Biol Blood Marrow Transplant. 2008 Nov;14(11):1245-52. doi: 10.1016/j.bbmt.2008.08.010.

4

A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.一项关于采用降低强度预处理方案，随后进行异基因干细胞移植治疗血液系统恶性肿瘤患者的研究，该方案使用Campath-1H作为移植物抗宿主病策略的一部分。

Biol Blood Marrow Transplant. 2006 Aug;12(8):868-75. doi: 10.1016/j.bbmt.2006.05.006.

5

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.在基于阿仑单抗的减低强度预处理后，HLA 错配无关供者是同种异体移植的一种可行的备选移植物来源。

Blood. 2010 Jun 24;115(25):5147-53. doi: 10.1182/blood-2010-01-265413. Epub 2010 Apr 6.

6

Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience.使用“袋内”Campath进行T细胞清除的清髓性异基因干细胞移植的长期随访：莱顿经验

Bone Marrow Transplant. 2006 Jun;37(12):1129-34. doi: 10.1038/sj.bmt.1705385.

7

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?在非清髓性预处理时代，阿仑单抗（Campath-1H）用于治疗淋巴系统恶性肿瘤？

Bone Marrow Transplant. 2002 Dec;30(12):797-804. doi: 10.1038/sj.bmt.1703733.

8

Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.采用减低强度预处理的异基因干细胞移植治疗慢性淋巴细胞白血病后的治疗相关死亡率及移植物抗白血病活性

Leukemia. 2003 May;17(5):841-8. doi: 10.1038/sj.leu.2402905.

9

Reduced-intensity conditioning allogeneic stem cell transplantation with donor T-cell depletion using alemtuzumab added to the graft ('Campath in the bag').采用阿仑单抗进行供体T细胞清除的低强度预处理异基因干细胞移植（“袋中坎帕奇”），即将阿仑单抗添加到移植物中。

Curr Opin Oncol. 2009 Jun;21 Suppl 1:S27-9. doi: 10.1097/01.cco.0000357472.76337.0e.

10

Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.复发难治性霍奇金淋巴瘤异基因造血干细胞移植的减低剂量预处理：阿仑单抗和供体淋巴细胞输注对长期结局的影响

Br J Haematol. 2007 Oct;139(1):70-80. doi: 10.1111/j.1365-2141.2007.06759.x.